Syncria is the fifth product to which HGS has substantial financial rights that has entered late-stage clinical development . It is a biological product generated from the genetic fusion of human albumin and modified human GLP-1 peptide , and is designed to act throughout the body to help maintain normal blood-sugar levels and to control appetite . Syncria was created by HGS using its proprietary albumin-fusion technology , and licensed to GSK in 2004 . HGS is entitled to fees and milestone payments that could amount to as much as $ 183 million - including $ 24 million received to date - in addition to single-digit royalties on worldwide sales if Syncria is commercialized .